Veeda Clinical Research Limited

Read Veeda Group's latest whitepaper on Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: Findings from a Phase II Study. We at Veeda Group are thrilled to share that we recently presented the results of the Phase II Study at the EHA Congress by Veeda Europe (Heads). It was a fantastic opportunity to discuss our findings and the potential impact of Belantamab Mafodotin in clinical practice. KEY FINDINGS - Belamaf could be a valid treatment option for this difficult-to-treat patient population. - Evaluating belamaf in combination with other active agents could allow for longer intervals between doses while maintaining or improving effectiveness and reducing ocular toxicity. Check out the latest whitepaper to know more on Efficacy and Safety of Belantamab Mafodotin Monotherapy: https://bit.ly/3Y3uJRk To know more, you can visit www.veedacr.com or write to us at info@veedacr.com. Author: Efstathios Kastritis Faidra Psarommati, Ioannis Ninos, Eleni Vasalou, Stavros Gkolfinopoulos, George Kouvatseas, Cristina Brenna, Giorgos Cheliotis, Ioannis Katagas, Heads, BIONEEDS INDIA PRIVATE LIMITED. EMN Partners in creating a healthier tomorrow. #VeedaGroup #ClinicalResearch #EHA2024 #Belamaf #GSK #Oncology #EMN #MedicalResearch #HealthcareInnovation #Conference #EHAHybridCongress #Madrid

Only 10 Days to go for our Webinar! We are excited to announce our highly anticipated webinar on Advanced Strategies in Bioanalysis of Biosimilars: Achieving Similarity through Robust Assays is just around the corner! Join us for an insightful session where we'll dive deep into the latest advancements and best practices in the field. Date: July 25, 2024 Time: 18:00 IST | 14:30 CET | 08:30 EDT Duration: ~60 mins Platform: Zoom 3 Reasons why you shouldn't miss this Webinar: - Gain insights into the importance of robust bioanalytical assays in achieving biosimilarity - Explore advanced strategies for optimizing bioanalytical methods - Understand regulatory considerations and expectations in biosimilar bioanalysis This is a great chance to learn from industry experts, ask questions, and connect with professionals from around the world. You’ll find out how advanced bioanalytical techniques can ensure biosimilarity and support successful biosimilar development. Don't miss out—register now and secure your spot https://bit.ly/3LfTQJh Jagadeesh Boda, Ph.D. To know more about us, visit www.veedacr.com or write to us at info@veedacr.com. Partners in creating a healthier tomorrow. #Webinar #Bioanalysis #Biosimilars #AdvancedAssays #IndustryWebinar #ExpertInsights #Networking #Innovation #ProfessionalDevelopment #BioanalysisExcellence #PharmaceuticalDevelopment #BioanalyticalMethods

In vitro ADMET / DMPK team at Veeda Biopharma offers routine to advanced DMPK studies for wide range of compound modalities and committed to accelerate the drug discovery process using cutting edge technologies and strategic partnerships. We support the entire drug discovery process from early stage to lead optimization and IND filing for both small and large molecules. Our services encompass a variety of mechanistic DMPK studies, including in vitro ADME and in vivo PK assessments, crucial for evaluating compound rankings, optimizing their properties, and progressing from initial promising hits to viable drug candidates. At Veeda, we understand the critical role that DMPK studies play in drug development and offer innovative, time-efficient and cost-effective solutions at every stage of drug discovery.   Interested in learning more about how our DMPK services can accelerate your drug development programs? Contact us today at info.Biopharma@veedacr.com for more information or visit www.veedacr.com Stay tuned for more updates and insights from Veeda Biopharma! Dr. Sanjib Banerjee Chandrasekhar Koduru Suryakant Kumar Gamlendra (Gamu) Mishra Padmasri S Chaithra Chowdappa Partners in creating a healthier tomorrow. #DrugDiscovery #DMPK #ADMET #PharmaResearch #Biopharma #DrugDevelopment #VeedaBiopharma #Veeda #VeedaCR

The 505(b)(2) pathway has played a pivotal role in reducing time and streamlining the approval process by allowing drug manufacturers to rely on existing clinical data or literature produced by other companies. Pharma companies have been extensively utilizing the 505(b)(2) pathway to enhance existing drug products based on key features such as dosing regimen, formulation, and route of administration.   Veeda Group has shown robust support for drug development via the 505(b)(2) pathway: -  Successfully completed 45 studies, including 14 complex studies -   Database of over 1,300 volunteers -   Proficiency in More Than 10 Therapy Areas -   Collaborated with 25+ Global Sponsors   To know more about our support in accelerating Complex Drug Development through the 505(b)(2) Pathway write to us at info@veedacr.com or visit us at www.veedacr.com Partners in creating a healthier tomorrow.   #Veeda #VeedaCR #505b2 #Complexstudies #DrugDevelopment #Veedagroup #ClinicalResearch

Haven't secured your spot yet for our upcoming webinar on Advanced Strategies in Bioanalysis of Biosimilars: Achieving similarity through robust assays? Don't worry, there's still time! Here's a sneak peek into what awaits you: 🔍 Webinar Highlights: - Impact of the Bioanalytical Assay Set-up on Clinical Endpoints: Gain insights into how assay design influences clinical outcomes. - Rationale Behind the One-Assay Approach: Explore the benefits of the one-assay approach and discover how the two-step approach can enhance and complement this strategy. - Critical Reagents: Understand how these key components can affect assay performance. - Regulatory Considerations: Learn about current regulatory expectations and considerations. Join us to step into the forefront of biosimilar development with valuable insights from industry leaders! Dr. Jagadeesh Boda, Ph.D. 📅 Save the Date: 25th July 2024 | 18:00 IST | 14:30 CET | 08:30 EDT 🔗 Register Now: https://bit.ly/3LfTQJh To know more about us, visit www.veedacr.com or write to us at info@veedacr.com. Partners in creating a healthier tomorrow. #Veeda #VeedaGroup #Webinar #Biosimilars #Bioanalysis #BioanalysisExcellence #PharmaceuticalDevelopment #BiosimilarBioanalysis #BioanalyticalMethods

𝐄𝐧𝐬𝐮𝐫𝐢𝐧𝐠 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐤𝐢𝐧𝐞𝐭𝐢𝐜 𝐒𝐭𝐮𝐝𝐢𝐞𝐬 𝐰𝐢𝐭𝐡 𝐑𝐞𝐯𝐞𝐫𝐬𝐞 𝐁𝐥𝐨𝐨𝐝 𝐆𝐫𝐨𝐮𝐩𝐢𝐧𝐠   We’re pleased to share insights from a recent brief co-authored by Veeda expert Dr. Hiren Mehta. This brief demonstrates the use of Reverse Blood Grouping (RBG) to identify plasma samples inadvertently switched between subjects in a pharmacokinetic study. This approach corrected sample misassignments, ensuring accurate bioequivalence results.   RBG serves as a reliable method for verifying sample integrity when real-time documentation is unavailable, enhancing the accuracy and reliability of data in bioequivalence studies.   Check out the full report to learn more about the role of RBG in maintaining data precision in pharmacokinetic research: https://bit.ly/3zwfVjX To know more about us, visit www.veedacr.com or write to us at info@veedacr.com. Charles DiLiberti Partners in creating a healthier tomorrow.    #Veeda #VeedaClinicalResearch #VeedaGroup #Pharmacokinetics #Bioequivalence #ClinicalResearch #VeedaBiopharma

Advanced Mammalian Protein Expression and Cell Line Development: Veeda Biopharma is dedicated to accelerating your biopharma innovations. We provide cutting-edge services including cloning, expression, and purification of recombinant proteins, and developing robust cell lines for biosimilars and biologics. One of the biggest challenges in this field is maintaining consistent product quality during scale-up. Veeda Biopharma addresses this by implementing stringent quality control measures and utilizing state-of-the-art technologies to ensure that our processes are reliable and reproducible at every scale.   Veeda Biopharma supports emerging biopharma companies in bringing their groundbreaking therapies to market. Let's connect and drive your projects forward together!   To know more about us, visit www.veedacr.com or write to us at info@veedacr.com.   Tandon, Ajay Dr. Sanjib Banerjee Naganath Mandi Rajkumar Agarwal Abhishek Gandhi, Ph. D. Gamlendra (Gamu) Mishra    Partners in creating a healthier tomorrow.   #Veeda #VeedaClinicalResearch #Biotechnology #MammalianEngineering #ProteinExpression #BiotechServices  #VeedaBiopharma #VeedaGroup

Patent expirations often lead to a shake-up within the pharmaceutical industry, compelling companies to diversify their revenue bases and prepare for the upcoming patent cliffs.   Several high-performing injectable drugs worth billions are set to lose their patent protection soon. Historically, the loss of patent protection for blockbuster drugs has introduced intense competition from both industry's leading players and emerging players   Check out our flyer for a detailed list of some of the top-performing molecules that will soon require extensive biosimilar studies, healthy volunteer ( Bioequivalence) studies, and patient trials https://bit.ly/3RS1LQN To know more, visit www.veedacr.com or write to us at info@veedacr.com Partners in creating a healthier tomorrow. #Veeda #Biotechnology #LifeSciences #VeedaBiopharma #VeedaGroup #Veedaclinicalresearch #biosimilars #InjectableDrugs

At the forefront of innovation, we support emerging biopharma companies in developing the next generation of biotherapeutics. Our expertise in cloning, recombinant protein expression optimization, and meticulous protein purification ensures your biotherapeutics maintain the highest quality and efficacy. With precise host cell characterization, we provide reliable and reproducible results to accelerate your path to market. Partner with us to drive breakthroughs in biotherapeutics ; 1.   Cloning and Expression of Heterologous Proteins Harnessing the power of molecular biology to express heterologous proteins with native structure and functionality. 2.   Recombinant Protein Expression Optimization Fine-tuning of media and feed, inducer concentration, and induction time and temperature to maximize the protein yield and quality. 3.   Protein Purification and Characterization Inclusion body solubilization and refolding, protein purification by various chromatography and employing SDS-PAGE and Western blotting techniques for precise protein analysis and verification. 4.   Host Cell Characterization Ensuring purity, strain identification, and accurate plasmid copy numbers for reliable and reproducible results. Tandon, Ajay Dr. Sanjib Banerjee Naganath Mandi Rajkumar Agarwal Abhishek Gandhi, Ph. D. Gamlendra (Gamu) Mishra Rajiv Bharadwaj, Ph.D Naganath Mandi Let's connect and explore the exciting possibilities in microbial biotechnology! To know more, visit www.veedacr.com or write to us at info@veedacr.com Partners in creating a healthier tomorrow. #Biotechnology #MicrobialEngineering #ProteinExpression #BiotechInnovation #LifeSciences #VeedaBiopharma #VeedaGroup #Veedaclinicalresearch #biosimilars #biologics #Biopharmaresearch #Emergingbiopharma

📢 Reminder: Don't Miss Our Upcoming Webinar! As the biosimilars market continues to evolve, understanding the pivotal role of robust bioanalytical methods in achieving biosimilarity is more crucial than ever. 🎓 Webinar Title: Advanced Strategies in Bioanalysis of Biosimilars: Achieving Similarity Through Robust Assays 🔍 Webinar Highlights: - Impact of the Bioanalytical Assay Set-up on Clinical Endpoints: Gain insights into how assay design influences clinical outcomes. - Rationale Behind the One-Assay Approach: Explore the benefits of the one-assay approach and discover how the two-step approach can enhance and complement this strategy. - Critical Reagents: Understand how these key components can affect assay performance. - Regulatory Considerations: Learn about current regulatory expectations and considerations. Join us to step into the forefront of biosimilar development with valuable insights from industry leaders! 📅 Save the Date: 25th July 2024 | 18:00 IST | 14:30 CET | 08:30 EDT Register Now : https://bit.ly/3xF77HV For more information, please visit www.veedacr.com or contact us at info@veedacr.com. Partners in creating a healthier tomorrow. #Veeda #VeedaGroup #Webinar #Biosimilars #Bioanalysis #BioanalysisExcellence #PharmaceuticalDevelopment #Biosimilarbioanalysis #Bioanalyticalmethods